Trials / Completed
CompletedNCT01908426
Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 707 (actual)
- Sponsor
- Exelixis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effect of Cabozantinib (XL184) compared with placebo on overall survival in subjects with advanced hepatocellular carcinoma who have received prior sorafenib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cabozantinib tablets | |
| DRUG | Placebo tablets |
Timeline
- Start date
- 2013-09-26
- Primary completion
- 2017-10-16
- Completion
- 2021-01-12
- First posted
- 2013-07-25
- Last updated
- 2021-05-06
- Results posted
- 2019-03-01
Locations
104 sites across 19 countries: United States, Australia, Belgium, Canada, France, Germany, Hong Kong, Ireland, Italy, Netherlands, New Zealand, Poland, Romania, Singapore, South Korea, Spain, Taiwan, Turkey (Türkiye), United Kingdom
Source: ClinicalTrials.gov record NCT01908426. Inclusion in this directory is not an endorsement.